Company profile: Highlight Therapeutics
1.1 - Company Overview
Company description
- Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
Products and services
- Clinical Trials: Phase 1-successful studies of BO-112 as monotherapy and Phase 1b with anti-PD1, with planned or ongoing trials in collaboration with external partners
- Collaborations: Multi-institutional partnerships with Merck & Co and UCLA to develop and investigate BO-112 across various clinical settings
- BO-112: RNA-based therapy that initiates immune responses against ‘cold’ tumors to make them ‘hot’ and visible, being explored as monotherapy and with checkpoint inhibitors.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Highlight Therapeutics
Pierian Biosciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including ChemoINTEL, a chemosensitivity assay that measures tumor cell apoptotic response to cytotoxic agents to aid chemotherapy selection; ImmunoINTEL, a flow cytometry-based platform that characterizes and quantifies immune and tumor cell populations for immunotherapy selection; and PathwayINTEL, a proteomic profiling assay that identifies oncogenic drivers to help select targeted or biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pierian Biosciences company profile →
U3 Pharma
HQ: Germany
Website
- Description: Provider of targeted cancer drug development and novel targeted therapeutics, based in Martinsried near Munich, Germany. Established in 2001, U3 Pharma develops a pipeline of targeted therapies grounded in discoveries by founder Professor Axel Ullrich. Since May 2008, the company has belonged to DAIICHI Sankyo Co., Ltd.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U3 Pharma company profile →
Cartesian Therapeutics
HQ: United States
Website
- Description: Provider of potent, safer cell therapy in and beyond oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cartesian Therapeutics company profile →
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
Azeria Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer drug development, creating a pipeline of therapies designed to selectively inhibit pioneer factors to aid treatment of breast and prostate cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azeria Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Highlight Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Highlight Therapeutics
2.2 - Growth funds investing in similar companies to Highlight Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Highlight Therapeutics
4.2 - Public trading comparable groups for Highlight Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →